Abstract
Estimated Costs of Severe Adverse Drug Reactions Resulting in Hospitalization in the Veterans Health Administration
Highlights
Prior studies on adverse drug reactions (ADRs) have focused on severe events requiring hospitalization[1-4]; many of these studies were small, involving few medical centers.[2,3] Information about costs by medication, symptom, or drug-symptom pair is limited
Author affiliations and article information are listed at the end of this article. This retrospective quality improvement study was performed from the Veterans Health Administration (VHA) perspective
Included ADRs from Veterans Affairs (VA) Adverse Drug Event Reporting System (ADERS) were linked to the likely corresponding VHA hospitalization and total costs based on patient identifiers and event date proximity (Figure)
Summary
Prior studies on adverse drug reactions (ADRs) have focused on severe events requiring hospitalization[1-4]; many of these studies were small, involving few medical centers.[2,3] Information about costs by medication, symptom, or drug-symptom pair (eg, lisinopril-angioedema) is limited. Prior studies on adverse drug reactions (ADRs) have focused on severe events requiring hospitalization[1-4]; many of these studies were small, involving few medical centers.[2,3]. Information about costs by medication, symptom, or drug-symptom pair (eg, lisinopril-angioedema) is limited. Within the Veterans Health Administration (VHA), VHA Directive 1070 requires reporting of ADRs to the Veterans Affairs (VA) Adverse Drug Event Reporting System (ADERS),[5] and these events can be integrated with other VHA clinical and economic data to inform decisions that may facilitate the prioritization of interventions to mitigate harm. We sought to estimate total medical costs for spontaneously reported severe ADRs by drug-symptom pair that resulted in or contributed to hospitalizations
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have